{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T02:59:32Z","timestamp":1770346772203,"version":"3.49.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["mdconsult.com","theclinics.com","derm.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.det.2014.09.008","type":"journal-article","created":{"date-parts":[[2014,11,18]],"date-time":"2014-11-18T04:45:37Z","timestamp":1416285937000},"page":"91-109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Current and Future Oral Systemic Therapies for Psoriasis"],"prefix":"10.1016","volume":"33","author":[{"suffix":"III","given":"John B.","family":"Kelly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Foley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce E.","family":"Strober","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.det.2014.09.008_bib1","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jaad.2009.03.027","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents","volume":"61","author":"Menter","year":"2009","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.det.2014.09.008_bib2","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/eurheartj\/ehp567","article-title":"Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the general practice research database","volume":"31","author":"Mehta","year":"2010","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.det.2014.09.008_bib3","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jaad.2013.06.053","article-title":"Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors","volume":"69","author":"Miller","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2014.09.008_bib4","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaad.2013.09.020","article-title":"From the Medical Board of the National Psoriasis Foundation: the risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies","volume":"70","author":"Hugh","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.det.2014.09.008_bib5","first-page":"1442","article-title":"Conventional systemic agents for psoriasis. A systematic review","volume":"33","author":"Strober","year":"2006","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.det.2014.09.008_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2013-204317","article-title":"Proposal for a new nomenclature of disease-modifying antirheumatic drugs","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.det.2014.09.008_bib7","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/ar419","article-title":"Molecular action of methotrexate in inflammatory diseases","volume":"4","author":"Chan","year":"2002","journal-title":"Arthritis Res"},{"issue":"1","key":"10.1016\/j.det.2014.09.008_bib8","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/art.10712","article-title":"Adenosine A2A or A3 receptors are required for inhibition of\u00a0inflammation by methotrexate and its analog MX-68","volume":"48","author":"Montesinos","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.det.2014.09.008_bib9","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1365-2230.2012.04440.x","article-title":"Efficacy and safety of systemic methotrexate in two fixed doses of 10 mg or 25 mg orally once weekly in adult patients with severe plaque-type psoriasis: a prospective, randomized, double-blind, dose-ranging study","volume":"37","author":"Dogra","year":"2012","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"10.1016\/j.det.2014.09.008_bib10","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s002280050404","article-title":"Pharmacokinetics of low doses of methotrexate in patients with psoriasis over the early period of treatment","volume":"53","author":"Chl\u00e1dek","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"issue":"Suppl 10","key":"10.1016\/j.det.2014.09.008_bib11","first-page":"1355","article-title":"Subcutaneous administration of methotrexate with a prefilled autoinjector pen results in a higher relative bioavailability compared with oral administration of methotrexate","volume":"65","author":"Pichlmeier","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"Suppl 3","key":"10.1016\/j.det.2014.09.008_bib12","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/annrheumdis-2013-eular.777","article-title":"Self-administered methotrexate using a medi-jet auto-injector improves bioavailability compared with oral methotrexate in adults with rheumatoid arthritis","volume":"72","author":"Schiff","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.det.2014.09.008_bib13","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/rheumatology\/36.1.86","article-title":"Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis","volume":"36","author":"Hamilton","year":"1997","journal-title":"Br J Rheumatol"},{"issue":"5 Suppl 61","key":"10.1016\/j.det.2014.09.008_bib14","first-page":"S27","article-title":"Methotrexate bioavailability","volume":"28","author":"van Roon","year":"2010","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.det.2014.09.008_bib15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/art.23144","article-title":"Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial","volume":"58","author":"Braun","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.det.2014.09.008_bib16","first-page":"483","article-title":"Comparative efficacy of subcutaneous versus oral methotrexate in active rheumatoid arthritis","volume":"22","author":"Islam","year":"2013","journal-title":"Mymensingh Med J"},{"issue":"4","key":"10.1016\/j.det.2014.09.008_bib17","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1111\/j.1756-185X.2010.01482.x","article-title":"Subcutaneous methotrexate is well tolerated and superior to oral methotrexate in the treatment of rheumatoid arthritis","volume":"13","author":"Hameed","year":"2010","journal-title":"Int J Rheum Dis"},{"issue":"4","key":"10.1016\/j.det.2014.09.008_bib18","first-page":"207","article-title":"Oral vs. subcutaneous low-dose methotrexate treatment in reducing gastrointestinal side effects","volume":"47","author":"Rutkowska-Sak","year":"2009","journal-title":"Rheumatolgia"},{"issue":"3","key":"10.1016\/j.det.2014.09.008_bib19","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/rheumatology\/keh088","article-title":"Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review","volume":"43","author":"Whittle","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.det.2014.09.008_bib20","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1002\/art.20516","article-title":"The effect of folic acid and folinic acid supplements on purine metabolism in methotrexate-treated rheumatoid arthritis","volume":"50","author":"Morgan","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.det.2014.09.008_bib21","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","article-title":"Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)","volume":"158","author":"Saurat","year":"2008","journal-title":"Br J Dermatol"},{"issue":"17","key":"10.1016\/j.det.2014.09.008_bib22","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJMoa1010858","article-title":"A\u00a052-week trial comparing briakinumab with methotrexate in patients with psoriasis","volume":"365","author":"Reich","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.det.2014.09.008_bib23","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/j.1365-2133.2011.10615.x","article-title":"Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1)","volume":"165","author":"Barker","year":"2011","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2014.09.008_bib24","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1365-2133.2011.10712.x","article-title":"Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy","volume":"166","author":"H\u00e9bert","year":"2012","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.det.2014.09.008_bib25","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1001\/jamadermatol.2014.681","article-title":"Methotrexate-induced liver toxicity: replacing the liver biopsy","volume":"150","author":"Strober","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"7","key":"10.1016\/j.det.2014.09.008_bib26","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1468-3083.2010.03932.x","article-title":"Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic","volume":"25","author":"Barker","year":"2011","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.det.2014.09.008_bib27","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jaad.2013.10.044","article-title":"Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: results from a population-based study","volume":"70","author":"Van der voort","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2014.09.008_bib28","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jhep.2007.01.024","article-title":"Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment","volume":"46","author":"Rosenberg","year":"2007","journal-title":"J\u00a0Hepatol"},{"issue":"7","key":"10.1016\/j.det.2014.09.008_bib29","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1056\/NEJMoa021359","article-title":"Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis","volume":"349","author":"Heydendael","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.det.2014.09.008_bib30","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/j.1468-3083.2010.03613.x","article-title":"Combining etanercept with traditional agents in the treatment of psoriasis: a review of the clinical evidence","volume":"24","author":"Foley","year":"2010","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"Suppl 83","key":"10.1016\/j.det.2014.09.008_bib31","first-page":"52","article-title":"Multidisciplinary focus on cyclosporin A","volume":"36","author":"Salvarini","year":"2009","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.det.2014.09.008_bib32","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.jaad.2010.02.063","article-title":"The use of cyclosporine in dermatology: part I","volume":"63","author":"Amor","year":"2010","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2014.09.008_bib33","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/art.23716","article-title":"Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate","volume":"59","author":"Buchbinder","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"Suppl 67","key":"10.1016\/j.det.2014.09.008_bib34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.0366-077X.2004.05949.x","article-title":"Ciclosporin in psoriasis clinical practice: an International Consensus Statement","volume":"150","author":"Griffiths","year":"2004","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2014.09.008_bib35","first-page":"116","article-title":"Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial","volume":"158","author":"Flytstr\u00f6m","year":"2008","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.det.2014.09.008_bib36","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1365-2230.2009.03693.x","article-title":"Methotrexate versus traditional Chinese medicine in psoriasis: a randomized, placebo-controlled trial to determine efficacy, safety and quality of life","volume":"35","author":"Ho","year":"2010","journal-title":"Clin Exp Dermatol"},{"issue":"12","key":"10.1016\/j.det.2014.09.008_bib37","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1111\/j.1468-3083.2010.03667.x","article-title":"Efficacy and safety of mycophenolate mofetil vs. methotrexate for the treatment of chronic plaque psoriasis","volume":"24","author":"Akhyani","year":"2010","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"10","key":"10.1016\/j.det.2014.09.008_bib38","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/j.1365-4632.2011.04967.x","article-title":"Weekly vs. daily administration of oral methotrexate (MTX) for generalized plaque psoriasis: a randomized controlled clinical trial","volume":"50","author":"Radmanesh","year":"2011","journal-title":"Int J Dermatol"},{"issue":"4","key":"10.1016\/j.det.2014.09.008_bib39","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1136\/ard.2011.152223","article-title":"Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study","volume":"71","author":"Baranauskaite","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.det.2014.09.008_bib40","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/09546630701499291","article-title":"Methotrexate versus hydroxycarbamide (hydroxyurea) as a weekly dose to treat moderate-to-severe chronic plaque psoriasis: a comparative study","volume":"18","author":"Ranjan","year":"2007","journal-title":"J\u00a0Dermatolog Treat"},{"issue":"1","key":"10.1016\/j.det.2014.09.008_bib41","first-page":"116","article-title":"Comparative efficacy of hydroxyurea and methotrexate in treating psoriasis","volume":"22","author":"Mahbub","year":"2013","journal-title":"Mymensingh Med J"},{"issue":"4","key":"10.1016\/j.det.2014.09.008_bib42","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1365-2133.2010.10195.x","article-title":"Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial","volume":"164","author":"Fallah Arani","year":"2011","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.det.2014.09.008_bib43","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1056\/NEJM199101313240501","article-title":"Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial","volume":"324","author":"Ellis","year":"1991","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.det.2014.09.008_bib44","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1046\/j.1365-2133.2001.04376.x","article-title":"Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial","volume":"145","author":"Reitamo","year":"2001","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.det.2014.09.008_bib45","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1080\/09546630701418747","article-title":"A\u00a0comparison of two cyclosporine dosage regimens for the treatment of severe psoriasis","volume":"18","author":"Yoon","year":"2007","journal-title":"J\u00a0Dermatolog Treat"},{"issue":"6","key":"10.1016\/j.det.2014.09.008_bib46","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/j.1468-3083.2006.01577.x","article-title":"Sequential study on the treatment of moderate-to-severe chronic plaque psoriasis with mycophenolate mofetil and cyclosporin","volume":"20","author":"Pedraz","year":"2006","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.det.2014.09.008_bib47","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000226134","article-title":"A\u00a0comparison of mycophenolate mofetil with ciclosporine for the treatment of chronic plaque-type psoriasis","volume":"219","author":"Beissert","year":"2009","journal-title":"Dermatology"},{"issue":"6","key":"10.1016\/j.det.2014.09.008_bib48","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10227-001-0147-1","article-title":"Psoriasis and pregnancy","volume":"6","author":"Tauscher","year":"2002","journal-title":"J\u00a0Cutan Med Surg"},{"issue":"8","key":"10.1016\/j.det.2014.09.008_bib49","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/00007890-200104270-00006","article-title":"Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis","volume":"71","author":"Baroz","year":"2001","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.det.2014.09.008_bib50","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/ijd.12365","article-title":"Acitretin in psoriasis: an evolving scenario","volume":"53","author":"Dogra","year":"2014","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2014.09.008_bib51","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0190-9622(88)70198-X","article-title":"Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study","volume":"19","author":"Gollnick","year":"1988","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2014.09.008_bib52","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000248398","article-title":"Benefit of progressively increasing doses during the initial treatment with acitretin in psoriasis","volume":"178","author":"Berbis","year":"1989","journal-title":"Dermatologica"},{"issue":"1","key":"10.1016\/j.det.2014.09.008_bib53","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1046\/j.1365-2133.1998.02030.x","article-title":"The effect of addition of calcipotriol ointment (50 micrograms\/g) to acitretin therapy in psoriasis","volume":"138","author":"Van de kerkhof","year":"1998","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.det.2014.09.008_bib54","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.1365-2133.1988.tb03499.x","article-title":"Acitretin and etretinate in the treatment of palmoplantar pustulosis: a double-blind comparative trial","volume":"119","author":"Lassus","year":"1988","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2014.09.008_bib55","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1365-2133.2012.11168.x","article-title":"Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study","volume":"167","author":"Papp","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2014.09.008_bib56","unstructured":"A phase 3, multi site, randomized, double blind, placebo controlled study of the efficacy and safety comparing CP-690,550 and etanercept in subjects with moderate to severe chronic plaque psoriasis. ClinicalTrials.gov. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01241591. Accessed May 10, 2014."},{"key":"10.1016\/j.det.2014.09.008_bib57","unstructured":"A study to evaluate the effects and safety of treatment, treatment withdrawal, followed by re-treatment with CP-690,550 in subjects with moderate to severe chronic plaque psoriasis. ClinicalTrials.gov. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01186744. Accessed May 10, 2014."},{"issue":"5","key":"10.1016\/j.det.2014.09.008_bib58","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/bjd.12517","article-title":"Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment","volume":"169","author":"Strober","year":"2013","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.det.2014.09.008_bib59","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","article-title":"Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"9843","key":"10.1016\/j.det.2014.09.008_bib60","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S0140-6736(12)60642-4","article-title":"Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial","volume":"380","author":"Papp","year":"2012","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.det.2014.09.008_bib61","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1185\/030079908X301866","article-title":"An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast","volume":"24","author":"Gottlieb","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.det.2014.09.008_bib62","unstructured":"Paul C, Cather J, Gooderham M, et\u00a0al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: 16-week results of a phase 3, randomized, controlled trial (ESTEEM 2). Poster presented at 72nd AAD Annual Meeting. Denver, CO. Available at: http:\/\/www.aad.org\/Posters\/Documents\/AM2014\/Poster\/8412\/8412. Accessed April 30, 2014."},{"key":"10.1016\/j.det.2014.09.008_bib63","unstructured":"Reich K, Papp K, Leonardi C, et\u00a0al. Long-term safety\u00a0and tolerability of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: Results from a Phase III, Randomized, Controlled Trial (ESTEEM 1). Poster presented at 72nd AAD Annual Meeting. Denver, CO. Available at: http:\/\/www.aad.org\/Posters\/Documents\/AM2014\/Poster\/8296\/8296. Accessed April 30, 2014."},{"key":"10.1016\/j.det.2014.09.008_bib64","unstructured":"Otezla [Package Insert]. NJ: Celgene Corporation, Summit; 2014."},{"issue":"1","key":"10.1016\/j.det.2014.09.008_bib65","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3109\/09546634.2012.723124","article-title":"Enteric-coated mycophenolate sodium in psoriasis vulgaris: an open pilot study","volume":"25","author":"Fallah arani","year":"2014","journal-title":"J\u00a0Dermatolog Treat"},{"issue":"3","key":"10.1016\/j.det.2014.09.008_bib66","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10227-002-0113-6","article-title":"Mycophenolate mofetil (CellCept) for psoriasis: a two-center, prospective, open-label clinical trial","volume":"7","author":"Zhou","year":"2003","journal-title":"J\u00a0Cutan Med Surg"},{"key":"10.1016\/j.det.2014.09.008_bib67","doi-asserted-by":"crossref","first-page":"685","DOI":"10.12659\/AOT.889299","article-title":"Mycophenolate mofetil in liver transplantation: a review","volume":"18","author":"Kaltenborn","year":"2013","journal-title":"Ann Transplant"},{"issue":"6","key":"10.1016\/j.det.2014.09.008_bib68","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/art.20253","article-title":"Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial","volume":"50","author":"Kaltwasser","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.det.2014.09.008_bib69","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2133.2009.09267.x","article-title":"Treatment of\u00a0severe, recalcitrant, chronic plaque psoriasis with fumaric acid esters: a prospective study","volume":"162","author":"Wain","year":"2010","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.det.2014.09.008_bib70","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/j.1365-2230.2012.04351.x","article-title":"Fumaric acid esters as a suitable first-line treatment for severe psoriasis: an Irish experience","volume":"37","author":"Heelan","year":"2012","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"10.1016\/j.det.2014.09.008_bib71","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0190-9622(94)70055-9","article-title":"6-Thioguanine treatment of psoriasis: experience in 81 patients","volume":"30","author":"Zackheim","year":"1994","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2014.09.008_bib72","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1440-0960.1988.tb00391.x","article-title":"Treatment of psoriasis with 6-thioguanine","volume":"29","author":"Zackheim","year":"1988","journal-title":"Australas J Dermatol"},{"issue":"4","key":"10.1016\/j.det.2014.09.008_bib73","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/archderm.135.4.433","article-title":"Pulse dosing of thioguanine in recalcitrant psoriasis","volume":"135","author":"Silvis","year":"1999","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.det.2014.09.008_bib74","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1001\/archderm.1990.01670280071013","article-title":"Sulfasalazine improves psoriasis. A double-blind analysis","volume":"126","author":"Gupta","year":"1990","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.det.2014.09.008_bib75","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3109\/09546630903460260","article-title":"Sulfasalazine and pentoxifylline in psoriasis: a possible safe alternative","volume":"22","author":"El-Mofty","year":"2011","journal-title":"J\u00a0Dermatolog Treat"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863514001144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863514001144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T14:21:36Z","timestamp":1538058096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863514001144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0733863514001144"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2014.09.008","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and Future Oral Systemic Therapies for Psoriasis","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2014.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}